AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Denali Therapeutics Inc.
Video analysis: DNLI
All videosNo video analysis for this stock yet. Request one from our team.
News: DNLI
BlackRock Inc. Takes Position in Denali Therapeutics Inc. $DNLI
BlackRock Inc. bought a new stake in Denali Therapeutics Inc. (NASDAQ: DNLI) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 14,026,413 shares of the company's stock, valued at approximately $360,759,000. BlackRock Inc. owned about 8.84% of Denali Therapeutics at the end
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
Denali Therapeutics: Bullish On Avlayah And Their Prospects
AVLAYAH's approval has helped validate Denali Therapeutics' TransportVehicle platform. They're now moving into their commercial stage as a business. Early payer coverage and Q3 guidance support a credible launch ramp. However, AVLAYAH's US label limits its near-term potential. Zafinofusp alfa and four TV-enabled 2027 readouts provide meaningful pipeline upside beyond AVLAYAH.
Head to Head Comparison: Denali Therapeutics (NASDAQ:DNLI) versus Humacyte (NASDAQ:HUMA)
Denali Therapeutics (NASDAQ: DNLI - Get Free Report) and Humacyte (NASDAQ: HUMA - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk. Analyst Recommendations This is a summary of recent recommendations
Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One
Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH's Q2 revenue of $3.6M is projected to triple in Q3, reflecting accelerating patient uptake and payer coverage progress. DNLI's TransportVehicle platform underpins a pipeline spanning enzymes, antibodies, and oligonucleotides, targeting both rare and large neurodegenerative markets.
Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction
On June 30, 2026, Baillie Gifford (Trades, Portfolio) executed a reduction of 106,249 shares in Denali Therapeutics Inc (NASDAQ: DNLI) at a traded price of $25.7
Denali Therapeutics Inc. $DNLI Shares Acquired by California State Teachers Retirement System
California State Teachers Retirement System increased its position in shares of Denali Therapeutics Inc. (NASDAQ: DNLI) by 25.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 162,576 shares of the company's stock after acquiring an additional 33,167 shares during the
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.
